Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 1 | 2014
LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant melanoma drug Keytruda (Merck & Co.’s pembrolizumab).
LaunchTrends: Keytruda measures the impact of this novel agent on the unresectable or metastatic malignant melanoma therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. The report evaluates physicians’ current awareness and perception of Keytruda relative to other currently available therapies for unresectable or metastatic malignant melanoma, current and anticipated use of Keytruda, and promotional activity of Keytruda.
Questions Answered:
- What is the awareness of and familiarity with Keytruda among medical oncologists?
- What are the perceived clinical advantages and disadvantages of Keytruda compared with other marketed agents used for treating unresectable or metastatic malignant melanoma?
- To what extent is Keytruda currently being used by surveyed medical oncologists? Where does Keytruda fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Keytruda?
- What promotional messages are being employed by Merck & Co.?
Scope:
Market covered: United States.
Primary research: 76 medical oncologists; qualitative interviews with 10 respondents.
Indication coverage: Unresectable or metastatic malignant melanoma.
